These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

363 related items for PubMed ID: 22079083

  • 1. Transgenic inactivation of murine myostatin does not decrease the severity of disease in a model of Spinal Muscular Atrophy.
    Rindt H, Buckley DM, Vale SM, Krogman M, Rose FF, Garcia ML, Lorson CL.
    Neuromuscul Disord; 2012 Mar; 22(3):277-85. PubMed ID: 22079083
    [Abstract] [Full Text] [Related]

  • 2. SAHA ameliorates the SMA phenotype in two mouse models for spinal muscular atrophy.
    Riessland M, Ackermann B, Förster A, Jakubik M, Hauke J, Garbes L, Fritzsche I, Mende Y, Blumcke I, Hahnen E, Wirth B.
    Hum Mol Genet; 2010 Apr 15; 19(8):1492-506. PubMed ID: 20097677
    [Abstract] [Full Text] [Related]

  • 3. Development and characterization of an SMN2-based intermediate mouse model of Spinal Muscular Atrophy.
    Cobb MS, Rose FF, Rindt H, Glascock JJ, Shababi M, Miller MR, Osman EY, Yen PF, Garcia ML, Martin BR, Wetz MJ, Mazzasette C, Feng Z, Ko CP, Lorson CL.
    Hum Mol Genet; 2013 May 01; 22(9):1843-55. PubMed ID: 23390132
    [Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5. Pharmacologically induced mouse model of adult spinal muscular atrophy to evaluate effectiveness of therapeutics after disease onset.
    Feng Z, Ling KK, Zhao X, Zhou C, Karp G, Welch EM, Naryshkin N, Ratni H, Chen KS, Metzger F, Paushkin S, Weetall M, Ko CP.
    Hum Mol Genet; 2016 Mar 01; 25(5):964-75. PubMed ID: 26758873
    [Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. Motor neuron pathology and behavioral alterations at late stages in a SMA mouse model.
    Fulceri F, Bartalucci A, Paparelli S, Pasquali L, Biagioni F, Ferrucci M, Ruffoli R, Fornai F.
    Brain Res; 2012 Mar 09; 1442():66-75. PubMed ID: 22306031
    [Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. Spinal muscular atrophy: from animal model to clinical trial.
    Zanoteli E, Maximino JR, Conti Reed U, Chadi G.
    Funct Neurol; 2010 Mar 09; 25(2):73-9. PubMed ID: 20923604
    [Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. Spinal muscular atrophy: a deficiency in a ubiquitous protein; a motor neuron-specific disease.
    Monani UR.
    Neuron; 2005 Dec 22; 48(6):885-96. PubMed ID: 16364894
    [Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. Celecoxib increases SMN and survival in a severe spinal muscular atrophy mouse model via p38 pathway activation.
    Farooq F, Abadía-Molina F, MacKenzie D, Hadwen J, Shamim F, O'Reilly S, Holcik M, MacKenzie A.
    Hum Mol Genet; 2013 Sep 01; 22(17):3415-24. PubMed ID: 23656793
    [Abstract] [Full Text] [Related]

  • 20. Cardiac defects contribute to the pathology of spinal muscular atrophy models.
    Shababi M, Habibi J, Yang HT, Vale SM, Sewell WA, Lorson CL.
    Hum Mol Genet; 2010 Oct 15; 19(20):4059-71. PubMed ID: 20696672
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 19.